Nine for 2025: nine key issues transforming global life sciences and healthcare next year and beyond

A review of nine issues which are new or see inflection points in 2025, transforming global life sciences, healthcare systems or the pharmaceutical industry in 2025 and beyond.

The review covers macro and environmental issues affecting global life sciences and healthcare, innovative and technology issues driving the Life Sciences and Pharma industries to deliver value to healthcare systems, and the critical business and competitive issues companies will face.

3 key areas of discussion:

• After 2024’s bumper set of elections across the world, what’s on the political agenda which will impact healthcare delivery and life sciences businesses in 2025 and beyond? How can the global pharmaceutical industry address an increasingly fragmented international landscape?
• What will be the therapeutic breakthroughs and key innovations of 2025 for the global pharmaceutical industry? What will the Obesity market, rapidly becoming one of the world’s most valuable therapeutic areas, evolve into in 2025? How will AI in healthcare and life sciences diverge and transform as regulation becomes a reality?
• How will the race for manufacturing capacity be a critical element of public and commercial strategy in an era of supply shortages and new mass prevalence disease innovation? How will pharma’s closer engagement with patients transform healthcare delivery and the pharmaceutical industry? What could happen to Life Sciences investment in 2025, and what are the implications?